Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | FABP7 | O15540 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29823996 | 0.89 | KMT2A (0.45) | KMT2AFABP5CASP3FABP7EPHX2 | |
| SCHEMBL15424391 | 0.83 | KMT2A (0.50) | KMT2AFABP5CASP3FABP7EPHX2 | |
| SCHEMBL15223383 | 0.81 | KMT2A (0.45) | KMT2AFABP5CASP3FABP7EPHX2 | |
| SCHEMBL29401774 | 0.79 | TLR2 (0.55) | KMT2ACASP3MDM4TP53TLR2 | |
| SCHEMBL29750297 | 0.79 | TLR2 (0.55) | KMT2ACASP3MDM4TP53TLR2 | |
| SCHEMBL31217659 | 0.79 | TLR2 (0.55) | KMT2ACASP3MDM4TP53TLR2 | |
| SCHEMBL29651368 | 0.79 | TLR2 (0.55) | KMT2ACASP3MDM4TP53TLR2 | |
| SCHEMBL1755686 | 0.79 | TLR2 (0.55) | KMT2ACASP3MDM4TP53TLR2 | |
| SCHEMBL13227676 | 0.79 | TLR2 (0.55) | KMT2ACASP3MDM4TP53TLR2 | |
| SCHEMBL29350848 | 0.79 | TLR2 (0.55) | KMT2ACASP3MDM4TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617819-B2 | Intermediate used for biologically active polypeptide and method for preparing same | HANMI FINE CHEMICAL CO., LTD. (KR) | 2026-05-05 | — | — | US | disclosed |
| US-20220242913-A1 | NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME | HANMI FINE CHEMICAL CO., LTD. (KR) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220242913-A1 | NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME | VIP, IAPP, ANPEP | KMT2A 4831/4885FABP5 1686/4885CASP3 4410/4885 |
| US-12617819-B2 | Intermediate used for biologically active polypeptide and method for preparing same | VIP, PTMS, HM13 | KMT2A 3953/4885FABP5 4405/4885CASP3 3781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.